BACKGROUND In EVEREST II (Endovascular Valve Edge-to-Edge Repair Study), treatment of mitral regurgitation (MR) with a novel percutaneous device showed superior safety compared with surgery, but less effective reduction in MR at 1 year.
T he MitraClip device (Abbott Vascular, Menlo Park, California) was developed as a percutaneous means to reduce mitral regurgitation (MR) by approximating the mitral valve (MV) leaflets.
The procedure is modeled after the surgical Alfieri double-orifice technique of MV repair, which has been shown to have durable results when performed in conjunction with an annuloplasty ring for degenerative MR (1, 2) . We previously reported the results of the randomized EVEREST II (Endovascular Valve Edge-to-Edge Repair Study), in which percutaneous MV repair using this percutaneous approach was compared with conventional surgery (3) (4) (5) . The primary outcome at 1 year demonstrated that conventional surgery was more effective than percutaneous repair for reducing MR. However, improvements in left ventricular (LV) remodeling and clinical outcomes were similar for both approaches and the percutaneous approach demonstrated a greater level of safety than did surgery (3) .
Several important clinical questions remain unanswered regarding percutaneous MV repair for moderate-to-severe MR. Given the increased prevalence of residual MR and the lack of annuloplasty with this device, the durability of percutaneous repair relative to conventional surgery, and the impact of MV repair technique on long-term survival, symptoms, and LV remodeling, is unknown.
We sought to address these questions based on the 5-year, final results of the EVEREST II randomized trial. STUDY PROCEDURE AND DEVICE. The percutaneous procedure was performed with the patient under general anesthesia using transesophageal echocardiography and fluoroscopic guidance in the cardiac catheterization laboratory, as previously described (3, (9) (10) (11) . Deployment of a second MitraClip device was permitted if the first did not result in an adequate reduction in MR. If residual MR $3þ was determined to be clinically unacceptable, the patient could undergo either a second procedure to place the second device or elective MV surgery. Patients were treated with aspirin, 325 mg daily, for 6 months and clopidogrel, 75 mg daily, for 30 days.
METHODS
ENDPOINTS. We compared treatment groups using the following endpoints through 5 years within the all-treated cohort: 1) freedom from death, surgery for MV dysfunction, and 3þ and 4þ MR; 2) freedom from death; 3) freedom from surgery for MV dysfunction; and 4) freedom from death and surgery for MV dysfunction. Additional pre-specified analyses include change in LV dimensions and volumes, New York Heart Association (NYHA) classification of heart failure (12) , and 36-item short-form health survey quality-of-life score (13) . Clinical and echocardiographic follow-up were mandated annually for 5 years.
All components of the primary safety and effectiveness endpoints were adjudicated by members of an independent clinical events committee or the core echocardiographic laboratory. STATISTICAL ANALYSIS. Comparisons were designed and powered with pre-specified effectiveness and safety margins. Surgery was expected to result in more complete MR reduction; however, percutaneous treatment was anticipated to have significantly lower procedural risk. Comparisons were performed within the all-treated cohort, which excludes patients who were randomized but not treated, to avoid bias toward the null. Results from the intention-to-treat cohort are presented in Online Table 1 . Twenty-four patients in each arm were excluded from this analysis as detailed in Figure 1 . The 5-year analysis of the all-treated cohort therefore included 154 (87%) and 56 (70%) patients in the device and surgical arms, respectively. Baseline clinical characteristics were well-balanced across treatment groups ( Table 1) . Survivors in both groups demonstrated significant reduction in MR from baseline to 12 months (paired p < 0.001 for both groups) and from baseline to 5 years (paired p < 0.001 for both groups), demonstrating the durability of MV repair with both the surgical and the percutaneous approaches. As previously reported, surgery proved to be more effective at 12 months because fewer patients had 3þ or 4þ MR after surgery than after percutaneous repair (0% vs. 17.9%; p ¼ 0.004). This difference remained at 5-year follow-up (2.5% vs. 18.8%; p ¼ 0.01) ( Figure 2A ).
Despite increased MR reduction with surgery,
NYHA functional class III/IV symptoms were more frequently experienced at 12 months with surgery compared with percutaneous repair (7.5% vs. 1.0%; Figure 2B ). At 5 years, a nonsignificant The EVEREST II RCT: Table 5 ).
DISCUSSION
The EVEREST II randomized trial evaluated the safety and efficacy of percutaneous MV repair using the MitraClip device relative to standard MV surgery (3, 4 I   II   III   IV   40%   I   II   III   IV   I   40%  II   III   I   II   III   I   II   III   I   II   III  1%  8%  9% Table 1 . Therefore, to better estimate the impact of each Tables 1 and 3 . Values are % (n/N) unless otherwise indicated. Table 1 .
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